A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These mutations are specific to non-HRD MM, and, notably, DIS3 is the only RNA exosome subunit associated with cancer2,42,43.”
From DIS3 mutations enhance AID-driven translocations during B-cell activation, promoting transformation to multiple myeloma (2026) · cites this paper as [42]
In the citing paper
“Furthermore, these mutations arise early in MM progression42,59, presumably driving the disease2,3,60.”
From DIS3 mutations enhance AID-driven translocations during B-cell activation, promoting transformation to multiple myeloma (2026) · cites this paper as [42]
In the citing paper
“These mutations are specific to non-HRD MM, and, notably, DIS3 is the only RNA exosome subunit associated with cancer2,42,43.”
From DIS3 mutations enhance AID-driven translocations during B-cell activation, promoting transformation to multiple myeloma (2026) · cites this paper as [42]
In the citing paper
“Ten to 20% of MM cases harbor somatic point mutations in the DIS3 gene.”
From DIS3 mutations enhance AID-driven translocations during B-cell activation, promoting transformation to multiple myeloma (2026) · cites this paper as [42]
In the citing paper
“Mechanistic studies reveal that DIS3-mutated MM cases exhibit a characteristic transcriptional profile consistent with dysregulation of RNA metabolism, including upregulation of long ncRNA [165,166].”
From The RNA exosome: mechanisms of RNA surveillance, regulation, and disease (2026) · cites this paper as [165]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
Lohr, J. G., Stojanov, P., Carter, S. L., Cruz-Gordillo, P., Lawrence, M. S., Auclair, D., Sougnez, C., Knoechel, B., Gould, J., Saksena, G., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.015 · Cited by 988
The genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
Bolli, N., Avet-Loiseau, H., Wedge, D. C., Van Loo, P., Alexandrov, L. B., Martincorena, I., Dawson, K. J., Iorio, F., Nik-Zainal, S., Bignell, G. R., et al. (2014) · Nature Communications · doi:10.1038/ncomms3997 · Cited by 875
Research works printed but not linked: 33
- Fonseca, 2011, Plasma cell leukemia, Blood Rev, 25, 107, 10.1016/j.blre.2011.01.005 · DOI
- Auclair, 2011, Initial genome sequencing and analysis of multiple myeloma, Nature, 471, 467, 10.1038/nature09837 · DOI · Paper page
- Carpten, 2012, Clonal competition with alternating dominance in multiple myeloma, Blood, 120, 1067, 10.1182/blood-2012-01-405985 · DOI · Paper page
- Morgan, 2012, Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma, Blood, 120, 1077, 10.1182/blood-2012-03-412981 · DOI · Paper page
- Tonon, 2015, Molecular spectrum of BRAF, NRAS, and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation, Oncotarget, 6, 24205, 10.18632/oncotarget.4434 · DOI
- Dziembowski, 2011, The eukaryotic RNA exosome: same scaffold but variable catalytic subunits, RNA Biol, 8, 61, 10.4161/rna.8.1.14237 · DOI · Paper page
- Dziembowski, 2014, Multiple myeloma-associated hDIS3 mutations cause perturbations in cellular RNA metabolism and suggest hDIS3 PIN domain as a potential drug target, Nucleic Acids Res, 42, 1270, 10.1093/nar/gkt930 · DOI · Paper page
- Carvalho, 2014, Gene-dosage dependent overexpression at the 13q amplicon identifies DIS3 as candidate oncogene in colorectal cancer progression Genes Chromosomes, Cancer, 53, 339
- Van Gorp, 2013, A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer—a study of the OVCAD consortium, BMC Cancer, 13, 178, 10.1186/1471-2407-13-178 · doi:10.1186/1471-2407-13-178
- Leich, 2015, The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma, Br J Haematol, 169, 57, 10.1111/bjh.13256 · DOI · Paper page
- Tonon, 2015, The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA, Nucleic Acids Res, 43, 5182, 10.1093/nar/gkv387 · DOI · Paper page
- Conti, 2008, Structure of the active subunit of the yeast exosome core, Rrp44: diverse modes of substrate recruitment in the RNase II nuclease family, Mol Cell, 29, 717, 10.1016/j.molcel.2008.02.018 · DOI · Paper page
- Neri, 2009, A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect, Genes Chromosomes Cancer, 48, 603, 10.1002/gcc.20668 · DOI · Paper page
- D'Auria, 2013, Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles, Am J Hematol, 88, 16, 10.1002/ajh.23339 · DOI · Paper page
- Seraphin, 2007, A single subunit, Dis3, is essentially responsible for yeast exosome core activity, Nat Struct Mol Biol, 14, 15, 10.1038/nsmb1184 · DOI · Paper page
- Bargou, 2013, Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules, Blood Cancer Journal, 3, e102, 10.1038/bcj.2012.47 · DOI
- Raimondo, 2015, Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns, Oncotarget, 6, 17543, 10.18632/oncotarget.4028 · DOI
- Grossniklaus, 2007, Genome-wide high-resolution mapping of exosome substrates reveals hidden features in the Arabidopsis transcriptome, Cell, 131, 1340, 10.1016/j.cell.2007.10.056 · DOI · Paper page
- Tollervey, 2006, Microarray detection of novel nuclear RNA substrates for the exosome, Yeast, 23, 439, 10.1002/yea.1369 · DOI
- Andrulis, 2010, Genome-wide analysis reveals distinct substrate specificities of Rrp6, Dis3, and core exosome subunits, RNA, 16, 781, 10.1261/rna.1906710 · DOI · Paper page
- Stetson, 2014, The SKIV2L RNA exosome limits activation of the RIG-I-like receptors, Nat Immunol, 15, 839, 10.1038/ni.2948 · DOI · Paper page
- Futreal, 2014, Differential and limited expression of mutant alleles in multiple myeloma, Blood, 124, 3110, 10.1182/blood-2014-04-569327 · DOI
- Guariglia, 2014, Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia, Leukemia, 28, 222, 10.1038/leu.2013.241 · DOI
- International Myeloma Working G, 2003, Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group, Br J Haematol, 121, 749, 10.1046/j.1365-2141.2003.04355.x · DOI · Paper page
- Salmon, 1975, A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival, Cancer, 36, 842, 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U · DOI · Paper page
- Neri, 2007, Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma, Br J Haematol, 136, 565, 10.1111/j.1365-2141.2006.06467.x · DOI
- De Luca, 2013, Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome, Clin Cancer Res, 19, 3247, 10.1158/1078-0432.CCR-12-3461 · DOI
- Neri, 2007, Molecular characterization of human multiple myeloma cell lines by integrative genomics: Insights into the biology of the disease, Genes Chromosomes & Cancer, 46, 226, 10.1002/gcc.20404 · DOI · Paper page
- Chiaramonte, 2014, Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line, Genes Chromosomes Cancer, 53, 154, 10.1002/gcc.22127 · DOI
- Neri, 2005, Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses, Genes Chromosomes Cancer, 42, 117, 10.1002/gcc.20123 · DOI
- Stelitano, 2005, Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma, Oncogene, 24, 2461, 10.1038/sj.onc.1208447 · DOI
- Ilariucci, 2014, High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications, Br J Haematol, 165, 629, 10.1111/bjh.12800 · DOI
- Chu, 2001, Significance analysis of microarrays applied to the ionizing radiation response, Proc Natl Acad Sci U S A, 98, 5116, 10.1073/pnas.091062498 · DOI · Paper page
Cited by
Regulation of long non-coding RNAs and genome dynamics by the RNA surveillance machinery
Nair, L., Chung, H., & Basu, U. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0209-0 · Cited by 203
Kuliński, T. M., Gewartowska, O., Mahé, M., Kasztelan, K., Durys, N., Stroynowska-Czerwińska, A., Jedynak-Slyvka, M., Owczarek, E. P., Chaudhury, D., Nowotny, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70386-3 · Cited by 7
The RNA exosome: mechanisms of RNA surveillance, regulation, and disease
Upadhyai, P., Quadri, N., & Chandran, D. (2026) · RNA Biology · doi:10.1080/15476286.2026.2685379 · Cited by 2
Metadata
- Authors
- Lionetti, M., Barbieri, M., Todoerti, K., Agnelli, L., Fabris, S., Tonon, G., Segalla, S., Cifola, I., Pinatel, E., Tassone, P., Musto, P., Baldini, L., & Neri, A.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-07-20
- Volume
- 6
- Issue
- 28
- Pages
- 26129-26141
- ISSN
- 1949-2553
- Cited by
- 49
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.